Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia☆☆☆

Mayo Clinic, Rochester, MN; Dana Farber Cancer Institute and Harvard Medical School, Boston, MA; The University of Texas M.D. Anderson Cancer Center, Houston, TX; Myeloma Institute for Research and Therapy, Little Rock, AR; Department of Medicine, Karolinska Hospital and Institutet, Stockholm, Sweden; Laboratory of Tumor Immunology and Immunotherapy, Rockefeller University, New York, NY; Department of Oncology, St Bartholomew's Hospital, London, UK; Biotechnology Research Laboratories, University Hospital IRCCS Policlinico San Matteo, Pavia, Italy; Department of Biochemistry, University of Pavia, Pavia, Italy; Service d'Hematologie Clinique, Centre Hospitalier Schaffner, Lens, France; Baylor Charles A. Sammons Cancer Center, Dallas, TX; and the Departement d'Hematologie, Hopital Pitie-Salpetriere, AP-HP, Paris, France

• Abstract
• Full Text
• PDF
• References